Published date: 10 December 2020
Last edited date: 19 May 2021
Awarded contract - This means that the contract has been awarded to a supplier.
Contract summary
Industry
Vaccines - 33651600
Location of contract
United Kingdom
Value of contract
£1
Procurement reference
4764/12/2020
Published date
10 December 2020
Closing date
16 November 2020
Closing time
12am
Contract start date
23 November 2020
Contract end date
31 December 2021
Contract type
Supply contract
Procedure type
Single tender action (below threshold)
A direct contract with a single supplier, without competition.
This procedure can be used for procurements below the relevant contract value threshold.
Contract is suitable for SMEs?
No
Contract is suitable for VCSEs?
No
Description
The procurement of the mRNA-1273 vaccine.
Award information
Awarded date
16 November 2020
Contract start date
23 November 2020
Contract end date
31 December 2021
Total value of contract
£1
This contract was awarded to 1 supplier.
Moderna Switzerland GmbH
Address
Moderna Switzerland GmbH, Aeschenvorstadt 48
4051 Basel
Switzerland
Company Number: CHE-344.522.989Reference
No reference - other
Value of contract
£1
Supplier is SME?
No
Supplier is VCSE?
No
Attachments
-
- Supply agreement SARS-CoV-2 mRNA Vaccine - [REDACTED].pdf
- Signed contract
- Supply agreement SARS-CoV-2 mRNA Vaccine - [REDACTED]
Additional details
-
Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vaccine vendors and (iii) impact fair competition between vaccine vendors .
Contract end date is being withheld on grounds that release of the information would be contrary to public interest under Regulation 50(6)(a). The contract end date is variable based on production and delivery of the requirement. There are significant challenges to overcome and the end date may not be a true reflection, setting unrealistic expectation for the public and in the market. This information is also being withheld on due to commercial sensitivity under Regulation 50(6)(b) and (c) as there is significant competition to develop and bring to the market a successful vaccine. Provision of the contract term may provide valuable information to competitors that may impact negotiations or future competition in the market.
Sub-contractor details are being withheld on grounds that release of the information would be contrary to public interest under Regulation 50(6)(a). This information is very sensitive given potential for targeting and disruption of the activities at the facilities which would be contrary to public interest as these activities are critical to success and delivery of the requirement.
Share this notice
Closing: 16 November 2020, 12am